Vcreate

Biotechnology Research

Designing the next generation of T-cell immunotherapies

View all 8 employees

About us

Website: https://vcreate.io
External link for Vcreate
Industry: Biotechnology Research
Company size: 2-10 employees
Type: Privately Held

Employees at Vcreate

Oleg Rogynskyy

Founder & CEO - SalesAI for Fortune500 ($200M, Andreessen, Iconiq, Lightspeed, YC - HIRING SALES LEADERS, AEs & ENGINEERS)
Gunsagar Gulati

Clinical Fellow in Hematology/Oncology at Dana-Farber Cancer Institute

See all employees

Updates

Vcreate

233 followers
3w
Report this post
Keep building!
Binbin Chen, MD, PhD

CEO, Co-founder at Vcreate.io
3w

Thanks to Merck Digital Science Studio for their support over the past ten months. We are grateful for the opportunity to connect with so many amazing founders, scientists, and investors all along the way. Sample pictures from our final demo day. Excited to meet our cohort 3 in the future! Ahmet Hamdi Cavusoglu Geof Hannigan, PhD Anita Manik, MBA, CPA Juan Alvarez Camella Wilson, PhD Prem Tumkosit, Carrie Williams, Northpond Ventures Microsoft for Startups Merck Global Health Innovation Fund, NJIT
Like Comment Share
Vcreate

233 followers
1mo
Report this post
Binbin Chen, MD, PhD

CEO, Co-founder at Vcreate.io
1mo Edited

This is a big deal: the first FDA-approved engineered cell therapy for solid tumors. What's more: it's for a patient population with urgent unmet needs!

Adaptimmune Receives U.S. FDA Accelerated Approval of TECELRA® (afamitresgene autoleucel), the First Approved Engineered Cell Therapy for a Solid Tumor

businesswire.com

Like Comment Share
Vcreate

233 followers
4mo
Report this post
We are excited to welcome Jonathan Schneck MD/PhD, Professor at Johns Hopkins Medicine and co-founder of NexImmune Inc. (NASDAQ: NEXI), to the Scientific Advisory Board of Vcreate. A pioneer in T cell biology, Dr. Schneck has developed crucial technologies such as artificial antigen presenting cells and artificial lymph nodes for advanced cancer immunotherapy. Technologies from the Schneck Lab enable the field to better activate and engineer anti-cancer T cells in vivo. We look forward to working with Dr. Schneck to advance our platform and build our asset portfolio. Dr. Schneck will join our other amazing advisors, including Russ Altman Eric Horvitz Lisa Wagar Michael Khodadoust Richard Yu Hanadie Yousef Gunsagar Gulati Ron Alfa, MD, PhD
13 Comments

Like Comment Share

Browse jobs

Funding

Vcreate 1 total round

Last Round

Pre seed Jun 6, 2021

See more info on crunchbase

Vcreate

Biotechnology Research

Designing the next generation of T-cell immunotherapies

About us

Employees at Vcreate

Oleg Rogynskyy

Founder & CEO - SalesAI for Fortune500 ($200M, Andreessen, Iconiq, Lightspeed, YC - HIRING SALES LEADERS, AEs & ENGINEERS)

Gunsagar Gulati

Clinical Fellow in Hematology/Oncology at Dana-Farber Cancer Institute

Updates

Adaptimmune Receives U.S. FDA Accelerated Approval of TECELRA® (afamitresgene autoleucel), the First Approved Engineered Cell Therapy for a Solid Tumor

businesswire.com

Join now to see what you are missing

Similar pages

Ascent Bio

Aperture Bio

Orbits Oncology

Prism.bio

Serinus Biosciences

Brainify.AI

Readout AI

DANNCE.ai

Nash

vCreate

Browse jobs

Account Manager jobs

Engineer jobs

Wordpress Developer jobs

Scientist jobs

SQL Developer jobs

Media Executive jobs

Funding